Updates: Senate Hearing for R&D Tax Incentive Bill (July – September 2020)
3 September 2020 A report was released today from the Senate Select Committee on Financial Technology and Regulatory Technology, chaired by Senator Andrew Bragg. This Committee was reviewing tax, regulation, capital and funding, skills and talent, and culture,…
Chad Briscoe, Ph.D. Joins BioAgilytix Leadership Team as Chief Scientific Officer
9 July 2020 BioAgilytix, a leading provider of contract bioanalytical testing services with specialization in large molecule bioanalysis, today announced that Chad Briscoe, Ph.D. has joined the organization’s leadership team as Chief Scientific Officer. In this role, Dr.…
CSIRO/Doherty Institute Select Recce Compounds for Priority 1 SARS-CoV-2 Antiviral Screening Program
9 July 2020 Highlights: • RECCE® 327 and New RECCE® 529 compounds were selected for their unique mechanism of actions against hyper-mutation, as indicated on bacteria and viruses (respectively) • Testing program will be conducted by CSIRO &…
Introducing BioMelbourne Network CEO Jeff Malone
Included in Insider – Thursday 9 July 2020 Hello, my name is Jeff Malone. I’m very excited to be taking the lead as the new CEO of BioMelbourne Network on 13 July. I bring with me almost 30…
Application granted for OMX Solutions TriFixTM Plating System inclusion on Prostheses List
7 July 2020 OMX Solutions Pty Ltd is delighted to announce the inclusion of its’ latest custom-made medical device (CMMD), the TriFixTM plating system, on the Prostheses List. The Prosthesis List and TriFixTM plating systems listing becomes effective…
LBT Teams With Global Clinical Diagnostic Company Beckman Coulter
7 July 2020 Australian medical technology company LBT Innovations Limited, a leader in medical technology automation using artificial intelligence, is pleased to announce a Marketing Agent Agreement with Beckman Coulter, Inc. (Beckman Coulter), a global leader in clinical…
In Fight Against COVID-19, CSL Behring Begins Trial to Evaluate Monoclonal Antibody (CSL312) for Respiratory Distress
6 July 2020 Global biotherapeutics leader CSL Behring today announced that the first patient has been enrolled in its Phase 2 study to assess the safety and efficacy of CSL312 (garadacimab, Factor XIIa antagonist monoclonal antibody) to treat patients suffering from severe…
ANDHealth releases the first detailed report on Australia’s digital health industry
3 July 2020 Three years in the making, ANDHealth are proud to bring you a brand new report – Digital Health: The Sleeping Giant of Australia’s Health Technology Industry. Packed with data and information we’ve collected from the…
KPMG – The Digital Delta Innovation Trends Survey 2020
3 July 2020 Business leaders in recent years have consistently indicated that innovation is amongst their top priorities. KPMG want to help you better understand how your Australian peers’ innovation perspectives and actions are changing, as we adjust…
Alterity Therapeutics meeting with US FDA provides development pathway for ATH434
30 June 2020 Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) is pleased to announce that it has received guidance from the US Food and Drug Administration (FDA) in relation to the development pathway for ATH434…
Acrux announces co-development agreement with Amring Pharmaceuticals Inc
2 July 2020 Acrux Limited a commercial-stage pharmaceutical company focused on developing generic topical drug products is pleased to announce that it has entered into an exclusive development and commercialisation agreement with Amring Pharmaceuticals, Inc. in the United…
Almac Group Launches Tempod 1000 to Improve Clinical Site Temperature Data Management
24 June 2020 Almac Clinical Services, part of the Almac Group, the global contract pharmaceutical development and manufacturing organization, has launched Tempod® 1000 which bolsters the company’s Site Compliance and temperature management offering for sponsors. An extension to Almac’s…
